Imagine shrinking a giant, expensive medical microscope down to the size of a computer chip. Instead of bulky lenses, it uses tiny light-guiding antennas and AI to create 3D images of cells. This allows doctors to spot cancer or infections in a tiny drop of fluid almost instantly.
Current biomedical imaging equipment is too bulky, expensive, and energy-intensive for point-of-care use or low-resource settings, delaying early cancer and infection diagnosis.
A CMOS-compatible on-chip tomographic microscope integrating wireless photonics, microfluidics, and AI for 3D cellular imaging.
If you are a device manufacturer dealing with the high cost and size of imaging equipment — this project developed a CMOS-compatible tomographic microscope that is dramatically cheaper, lighter, and smaller. It enables high-resolution cell analysis in low-resource settings.
If you are a research lab dealing with low throughput in immunocyte phenotyping — this project developed an integrated on-chip imaging system that increases parallelisation and energy efficiency. It allows for faster identification of stem cell multipotency.
If you are a provider dealing with the lack of diagnostic tools in remote areas — this project developed a mechanically robust, compact imaging chip. This allows for early cancer diagnosis and tissue pathology without needing a full hospital laboratory.
The technology uses CMOS compatibility, which ensures the resulting microscopes are dramatically cheaper than current approaches.
Yes, the project specifically highlights that the device is intrinsically mass-producible due to its on-chip design.
Based on available project data, specific licensing terms are not mentioned, but the project involves 2 SMEs and 3 research institutions developing the core technology.
It combines wireless photonics with microfluidics and AI, allowing it to be integrated into lab-on-a-chip systems for automated biological analysis.
The project period runs from 2022-12-01 to 2026-05-31, suggesting the technology is currently in the development and validation phase.
The consortium is well-balanced for technology transfer, featuring a 33% industry ratio with 2 SMEs and 4 research/academic partners across 3 countries (ES, DE, IT). The inclusion of two cancer R&D medical institutions ensures that the technical development is directly aligned with clinical validation needs.
Contact Universitat Politècnica de València
Contact us to explore licensing opportunities for CMOS-compatible bioimaging.
